731 related articles for article (PubMed ID: 25432519)
1. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
[TBL] [Abstract][Full Text] [Related]
2. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
4. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
[TBL] [Abstract][Full Text] [Related]
7. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
9. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Chan MS; Chen SF; Felizola SJ; Wang L; Nemoto N; Tamaki K; Ishida T; Chow LW; Ohuchi N; Sasano H
Int J Biol Markers; 2014 Sep; 29(3):e193-203. PubMed ID: 24803281
[TBL] [Abstract][Full Text] [Related]
10. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.
Rustamadji P; Wiyarta E; Pramono M; Maulanisa SC
Asian Pac J Cancer Prev; 2024 May; 25(5):1607-1613. PubMed ID: 38809632
[TBL] [Abstract][Full Text] [Related]
11. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
[TBL] [Abstract][Full Text] [Related]
12. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
Demaria S; Volm MD; Shapiro RL; Yee HT; Oratz R; Formenti SC; Muggia F; Symmans WF
Clin Cancer Res; 2001 Oct; 7(10):3025-30. PubMed ID: 11595690
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
15. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
16. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
17. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
Zhu S; Lin J; Qiao G; Xu Y; Zou H
Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
[TBL] [Abstract][Full Text] [Related]
20. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
